🇺🇸 FDA
Pipeline program

NMD670, NMD670, Placebo

NMD670-02-0002

Phase 2 small_molecule active

Quick answer

NMD670, NMD670, Placebo for Myasthenia Gravis is a Phase 2 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Myasthenia Gravis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials